
SXTP Stock Forecast & Price Target
SXTP Analyst Ratings
Bulls say
60 Degrees Pharmaceuticals Inc. reported revenues of $310,000, marking a significant 20% increase sequentially and a remarkable 145% year-over-year growth, indicating strong momentum in the company's financial performance. The firm is expected to benefit from reduced research and development expenses, leading to a revised fiscal year 2025 earnings per share (EPS) estimate improvement from $(5.32) to $(2.72). Despite a slight reduction in revenue forecasts for FY25, the positive adjustments to earnings estimates reflect confidence in the company's operational efficiency and prospects in developing therapies for infectious diseases.
Bears say
60 Degrees Pharmaceuticals Inc is experiencing sequential declines in product revenues, which fell to $100,000 owing to supply constraints, raising concerns about the firm's revenue ramp and overall financial stability. Additionally, the company lacks visibility on regulatory approvals for its pipeline products, underscoring potential risks associated with future revenue streams. Furthermore, the possibility of financing-related dilution poses an additional threat to the stock, diminishing outlook for investors.
This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
SXTP Analyst Forecast & Price Prediction
Start investing in SXTP
Order type
Buy in
Order amount
Est. shares
0 shares